A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
- Krepler, Clemens
- Sproesser, Katrin
- Brafford, Patricia
- Beqiri, Marilda
- Garman, Bradley
- Xiao, Min
- Shannan, Batool
- Watters, Andrea
- Perego, Michela
- Zhang, Gao
- Vultur, Adina
- Yin, Xiangfan
- Liu, Qin
- Anastopoulos, Ioannis N
- Wubbenhorst, Bradley
- Wilson, Melissa A.
- Xu, Wei
- Karakousis, Giorgos
- Feldman, Michael
- Xu, Xiaowei
- Amaravadi, Ravi
- Gangadhar, Tara C.
- Elder, David E.
- Haydu, Lauren E.
- Wargo, Jennifer A.
- Davies, Michael A.
- Lu, Yiling
- Mills, Gordon B.
- Frederick, Dennie T.
- Barzily-Rokni, Michal
- Flaherty, Keith T.
- Hoon, Dave S.
- Guarino, Michael
- Bennett, Joseph J.
- Ryan, Randall W.
- Petrelli, Nicholas J.
- Shields, Carol L.
- Terai, Mizue
- Sato, Takami
- Aplin, Andrew E.
- Roesch, Alexander
- Darr, David
- Angus, Steve
- Kumar, Rakesh
- Halilovic, Ensar
- Caponigro, Giordano
- Jeay, Sebastien
- Wuerthner, Jens
- Walter, Annette
- Ocker, Matthias
- Boxer, Matthew B.
- Schuchter, Lynn
- Nathanson, Katherine L
- Herlyn, Meenhard
DOIAbstract
Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further advancements through pre-clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) and live tissue samples from 384 patients representing the full spectrum of clinical, therapeutic, mutational, and biological heterogeneity of melanoma. PDX have been characterized using targeted sequencing and protein arrays and are clinically annotated. This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-re...